Skip to main content

Table 1 General information for the non-diabetic individual A and the four diabetic patients B–E

From: Personalizing the safe, appropriate and effective concentration(s) of ozone for a non-diabetic individual and four type II diabetic patients in autohemotherapy through blood hemoglobin analysis

Samples Age Gender Hb concentration (mg/ml) based on absorbance reading at 280 nm post ozonation and dialysis TAC (mM) Duration of disease (medication taken)
Individual A 46 Male Non-O3: 100.70
15 μg/ml O3: 136.48
35 μg/ml O3: 110.01
55 μg/ml O3: 111.48
0.274 ± 0.009
Patient B 56 Female Non-O3: 86.63
15 μg/ml O3: 79.61
35 μg/ml O3: 103.14
55 μg/ml O3: 75.38
0.207 ± 0.006 18 years
(Metformin)
Patient C 66 Male Non-O3: 66.12
15 μg/ml O3: 94.41
35 μg/ml O3: 80.59
55 μg/ml O3: 70.15
0.341 ± 0.015 20 years
(Insulin)
Patient D 60 Male Non-O3: 48.41
15 μg/ml O3: 63.92
35 μg/ml O3: 74.52
55 μg/ml O3: 86.88
0.370 ± 0.013 1 year
(Metformin)
Patient E 41 Female Non-O3: 62.80
15 μg/ml O3: 59.38
35 μg/ml O3: 57.40
55 μg/ml O3: 55.65
0.271 ± 0.029 5 years
(Insulin)